ved
Srivastava,博士
Intarcia Therapeutics,Inc。肽化学副总裁
轮廓
Ved Srivastava博士是Intarcia Therapeutics肽化学副总裁。在此之前,他是美国葛兰素史克林的肽化学负责人。并在美国的Amylin Pharmaceuticals(Astra Zeneca)担任领导职务。Ved is President-Elect of the American Peptide Society.
VED已经大量参与了Symlintm,ByetTATM和Bydeureontm的开发和商业化,这是治疗糖尿病的一流药物。VED在代谢疾病,中枢神经系统和炎症的药物发现和发育方面拥有25年以上的经验,并主要重点是肽化学,肽药物输送和化学制造和对照(CMC)。vedis the Editor of four books (1) Peptide-based Drug Discovery - Challenges and New Therapeutics, (2) Comprehensive Medicinal Chemistry IIIrd edition, Volume 6. Biologics Medicine (3) ‘Peptide 2015’ and (4) Peptide Therapeutics: Strategy and Tactics for Chemistry Manufacturing and Control (in print). Ved earned a Ph.D. in organic chemistry from the University of Lucknow, India.